The Patent Finder

Terms ending in 2030

Aventis Pharma S.A.

Every in-force patent on Aventis Pharma S.A.'s record whose computed term ends in 2030, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 8,481,589Novel Taxoid-Based Compositions
In force
 · High confidence
Aventis Pharma S.A.In forceHigh confidence
US 8,927,592Novel Antitumoral Use of Cabazitaxel
In force
 · Medium confidence
Sanofi Mature IPIn forceMedium confidence
US 10,583,110Novel Antitumoral Use of Cabazitaxel
In force
 · High confidence
Sanofi Mature IPIn forceHigh confidence
US 10,716,777Novel Antitumoral Use of Cabazitaxel
In force
 · Medium confidence
Sanofi Mature IPIn forceMedium confidence
4 of 4 patents shown. Soonest term end first, then patent number.
1 of these is in force and held by Aventis Pharma S.A..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited